Effects of Tirofiban Intracoronary Administration on the Interventional Therapy and Peripheral Blood PMPs Level in Patients with Acute ST-segment Elevation Myocardial Infarction

Abstract

Abstract: Objective To investigate the effects of tirofiban intracoronary administration on the interventional therapy and peripheral blood PMPs level in patients with acute ST-segment elevation myocardial infarction. Methods Totally 124 STEMI patients undergoing PCI were selected and divided into control group (n=62) and tirofiban group (n=62), the tirofiban group was received tirofiban combined PCI and the control group was treated with PCI. The basic clinical features before PCI, the thrombolysis in myocardial infarction (TIMI) flow grade 3, corrected TIMI flow counting frame count (CTFC), myocardial perfusion (TMPG) grade 3, resolution of the sum of ST-segment elevation (sumSTR) in 90 minutes; peak-value and peak-time of phosphoric acid creatine kinase isoenzyme (CK-MB), peak-value of cardiac troponin I (cTnI), the left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD) and left ventricular end-systolic diameter (LVESD) after PCI were observed and compared between the two groups. The peripheral blood PMPs levels before and after PCI were analyzed, as well as major adverse cardiovascular events (MACE) and incidence of bleeding within 3 months after PCI were observed and compared between the two groups. Results There was no statistical difference in basic clinical features between the two groups before PCI. The incidence rate of TMPG grade 3, TIMI grade 3 and sumSTR>50% in the tirofiban group were significantly higher than those of the control group (P <0.05), CTFC was significantly lower than that of the control group (P <0.05). The level of LVEF of the tirofiban group was significantly higher than that of the control group after operation, while the LVESD and LVEDD were significantly lower than those of the control group after operation (P <0.05). There was no significantly difference of PMPs levels before PCI between the two groups, the PMPs levels of the two group after operation were significantly lower than those of the preoperation, as well as the tirofiban group were significantly lower than that of the control group (P <0.05). The incidence rate of MACE was significantly lower in tirofiban group than that in control group within 3 months postoperatively. There was no significantly difference of incidence rate of bleeding between the two groups（P >0.05）. Conclusion In patients with STEMI, tirofiban intracoronary administration can significantly improve myocardial reperfusion , inhibit the PMPs level and incidence rate of MACE, and would not increase the incidence of bleeding complications, it is safe and effective in STEMI patients treated with PCI.

Key words: myocardial infarction, percutaneous coronary intervention, tirofiban, platelet microparticle

CLC Number:

R969.4

GUO Hua, WANG Tong, SUN Xiao-mei. Effects of Tirofiban Intracoronary Administration on the Interventional Therapy and Peripheral Blood PMPs Level in Patients with Acute ST-segment Elevation Myocardial Infarction[J]. Chinese Journal of Pharmacovigilance, 2017, 14(3): 145-149.

References

[1] Candemir B, Kilickap M, Ozcan O U, et al. Intracoronary versus intravenous high dose bolus plusmaintenance administration of tirofiban in patients undergoing primary percutaneous coronary intervention for acute ST elevation myocardial infarction[J]. Journal of Thrombosis and Thrombolysis, 2012, 34(1):65-2.
[2] 王子超,郝毅,张文祥,等. 冠状动脉介入术联合冠状动脉内注入替罗非班治疗急性ST段抬高性心肌梗死的临床观察[J]. 中华老年医学杂志, 2011, 30(5):416-419.
[3] 米翔. 冠心病介入治疗的临床研究进展[J]. 微创医学, 2011,6(5): 437-439.
[4] 刘君, 李冬义, 靳文,等. 早期应用替罗非班对ST段抬高性心肌梗死患者行急诊经皮冠状动脉介入治疗后的疗效[J]. 岭南心血管病杂志, 2014, 20(1):40-43.
[5] 马震, 阳海红, 张雷雨. 老年急性ST段抬高型心肌梗死急诊PCI术后不同途径应用替罗非班的疗效[J]. 中国老年学, 2015, 32(8):2023-2025.
[6] 官功昌, 刘棣, 张学军,等. 冠状动脉内注射替罗非班改善直接PCI患者近期预后临床研究[J]. 陕西医学杂志, 2013, 42(5): 566-568.
[7] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南[J]. 中华心血管病杂志, 2010, 38(8):675-690.
[8] 樊瑞丽,张晓. 半剂量替罗非班对冠心病患者介入治疗后血管内皮功能的影响[J]. 河南医学研究, 2014, 23(8):23-25.
[9] Madhavan M V, Kirtane A J. Post-PCI antithrombotic therapy in patients requiring long-term anticoagulation[J]. Current Cardiology Reports, 2015, 17(6):1-10.
[10] 尤威,叶飞,陈绍良,等. 直接冠脉内注射替罗非班在急性心肌梗死患者急诊PCI中治疗疗效的研究[J]. 安徽医药, 2013, 17(7):1209-1211.
[11] 刘红彬,刘志红,籍振国,等. 替罗非班应用时间对急性ST段抬高型心肌梗死患者PCI围术期临床疗效及短期预后的影响[J]. 山东医药, 2012, 52(45):36-38.
[12] 刘振江,周胜华,沈向前. 替罗非班对急性ST段抬高型心肌梗死患者介入治疗术后心肌组织灌注水平的影响[J]. 临床心血管病杂志, 2007, 23(6):417-419.
[13] Gao L, Cao Z, Zhang H. Efficacy and safety of thrombectomy combined with intracoronary administration of tirofiban in ST-segment elevation myocardial infarction(STEMI)[J]. Medical Science Monitor International Medical Journal of Experimental & Clinical Research, 2016, 22(3):2699-2705.